1/190
Looks like no tags are added yet.
Virus Host Cell
can be animal, plant, fungal, bacteriophage
Virus Structure
geometrical shape of capsid (helical or icosahedron); absence or presence of an envelope (phospholipid bilayer from host cell)
Virus Nucleic Acid Types
DNA, RNA, reverse transcribing
DNA Viruses
double stranded and less common single stranded
RNA Viruses
positive sense single stranded, negative sense single stranded, and less common double stranded
Reverse Transcribing Viruses
double stranded DNA, single stranded RNA
Viral Genome
small in size; biggest is the mimvirus (~100 Kb) and smallest is the circovirus
Viral Nucleic Acid
genetic material of all viruses; single or double stranded DNA or RNA; linear or circular
Virus Protein Coat (Capsid)
protein shell that protects the nucleic acid; composed of repeating viral proteins (capsomeres) encoded by the viral genome
Virus Envelope
present in some viruses; host derived phospholipid bilayer with viral glycoproteins
Virion
viral particle; consists of envelope glycoproteins, envelope, capsid, and viral nucleic acid
Advantages of Virion Structure
protection of the fragile nucleic acid genome from physical, chemical, or enzymatic damage; specificity/recognition and first interaction with host cell; delivery of genome into the cell
Viruses - A Problem
nucleotides have approximately 3x the mass of amino acid residues; viral capsids have limited space for packaging the genome
Virus Subunits
construction is based upon hydrophobic and electrostatic interactions; all viruses important in human disease have capsids
General Virus Replication Cycle
attachment and entry → uncoating and genome release → genome replication and protein synthesis → envelope glycoprotein synthesis and processing (ER) → assembly of nucleocapsid with genome → budding and maturation (ER/Golgi/PM) → mature virion release
Antibodies
a large protein produced by the immune system to identify and neutralize foreign objects (antigens); IgG and IgM
IgG
majority of the antibody response to pathogens
IgM
early stages of antibody-based immune reaction
Immunogenicity
ability of a substance to induce an adaptive immune response
Complete Antigens
proteins, polysaccharides, and lipids
Haptens
incomplete antigens; small molecules (various drugs like penicillin)
Passive Immunization
preformed antibodies from an external source; immediate protection, no memory; maternal IgG from placenta, maternal IgA from breastmilk, therapeutic antiserum/monoclonal antibodies
Active Immunization
exposure to antigen (infection or vaccine); induced the body to produce antibodies and cell-mediated responses; generates long lasting immunity (B and T Cells)
How Do We Measure Virus Neutralization?
viruses that are cytotoxic can be quantified by plaque-forming essays
Plaque Forming Units (PFU)
a measure of the number of infectious virus particles; determined by an assay in which infectious virus produces zones of infected-cell lysis in a cell monolayer
Multiplicity of Infection (MOI)
the average number of virus particles/infectious units infecting each cell; equals the PFU of virus used for infection/number of cells
IC50
half maximal inhibitory concentration; measure of the potency of a substance in inhibiting a specific biological or biochemical function; indicates how much of an inhibitory substance is needed to stop a biological process by 50%
PRNT50 Assay
gives us a way to compare the effectiveness of inhibitors; example → a patient’s antibodies
Hepatitis Viruses
vowels are acute, consonants are chronic; AB have vaccines
Hepatitis
inflammation of the liver; can lead to encephalopathy, eye jaundice, muscle aches and weakness, inflammation and bleeding of the esophagus, jaundice of the skin, spleen enlargement, stomach/pancreas inflammation
Hepatits A Virus (HAV)
fecal oral transmission, widespread subclinical infections; incubation period is 15-45 days; acute infection only; non-enveloped; icosahedral capsid (VP1-4); + ssRNA (picornavirus)
HAV - Immune Response
IgM antibodies are detectable first (acute infection); IgG antibodies are detectable for life (lasting immunity)
HAV - Diagnosis
serology - raised IgM and IgG (6 weeks after symptom onset); elevated liver enzymes, especially ALT
HAV - Virus Oddity
requires an intact eukaryote initiating factor 4g for initiation of translation; cannot shut fown host cell translation; must compete with the cell for elF4G; no cytotoxicity
Hepatitis Viruses - Membrane Hijacking
new evidence that HAV and HEV (and polio) exist outside the cell in two equally infectious forms; one enveloped, one not; they circulate in the blood in a membrane bound form and are shed in the feces without an envelope
HAV - Treatment
no specific method; rest, avoid alcohol and any toxic substances; over 85% of people recover within 3 months, nearly all patients recover within 6 months
HAV - Prevention
passive immunization from human gamma globulin; active immunization from vaccine (age > 1 year) and combined vaccine with HBV (age 18 years and over)
Hepatits B Virus (HBV)
major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma; incubation period is 45-160 days
HBV - Transmission
bloodborne, infectious blood or body fluids (semen, vaginal fluids); perinatal infection; also via close contact (sharing utensils, kissing, higging, breastfeeding)
HBV - Clinical Symptoms
appetite loss, fatigue, fever (low grade), muscle or joint aches, nausea and vomiting, jaundice (yellow skin) and dark urine
HBV - Immune Response
IgG (anti-HBs) antibodies usually persist for life after infection or immunization
HBV - Diagnosis
liver function tests (ALT elevation); serology (HBsAg, anti-HBc, anti-HBs) and/or viral DNA
HBV - Virion Structure
partially double stranded DNA genome; HBcAg capsid; polymerase (reverse transcriptase); HBsAg surface proteins; secretes HBeAg; HBx regulatory proteins
HBV - HBsAg Surface Proteins
all three share the S region - major antigenic determinant
HBV - Particle Types in the Blood
dane particle (infectious virion); spherical subviral particle (HBsAg only); filamentous subviral particle (HBsAg only)
HBV - Viral Hepatitis B
infects about a third of the worlds population some time in their lives; replicate through an RNA intermediate by activity of reverse transcriptase which relates them to retroviruses like HIV; partially dsDNA molecule genome and has a virion-associated DNA polymerase; 350 million are chronic carriers
HBV - Asymptomatic/Subclinical Infection
majority of infectious; HBsAg in serum for a short time (1-2 months); antibodies against HBsAg persist for life providing lifelong immunity
HBV - Acute Infection
long incubation period (43-180 days); symptoms as in acute hepatitis A; HBsAg in serum for 6 months (transient); majority of patients recover; antibodies against HBsAg persist for lifetime providing lifelong immunity
Fulminant Hepatitis
HBV + HDV; sudden and quick, intense and severe to point of lethality
HBV - Chronic Infection
one of the common long term results of acute infection is called persistent viral hepatitis; HBsAg in serum persists for over 6 months, probably for life
HBV - Treatment
interferon alpha (decreases stability of viral genome, causes side effects); nucleoside/nucleotide analogs whihc inhibit reverse transcriptase (initially HIV treatment); still work to determine optimal strategies
HBV Prevention - Recombivax
recombinant HBV surface antigen; traditional hep B vaccine
HBV Prevention - Engerix
recombinant HBsAg; similar antigen, different formulation
HBV Prevention - Twinrix
inactivated HAV and recombinant HBV HBsAg; combined HAV and HBV vaccine
HBV Prevention - Hepilsav
recombinant HBsAg + adjuvant; two dose adult series, generally one month apart
HCV - Transmission
IV drug use, blood transfusion (in countries without screening), tattooing with non-sterile equipment, sharing razors, manicure/pedicure equipment (parenteral)
HCV - Clinical Symptoms
right upper quadrant abdominal pain; ascites/abdominal swelling; clay colored or pale stools; dark urine, fatigue, fever, itching, jaundice; loss of appetite, nausea, vomiting
HCV - Immune Response
IgG antibodies usually persist for life after infection
HCV - Diagnosis
blood tests (antibodies); liver function tests; genetic testing (six genotypes, 1 is common in U.S., 2 and 3 are easier to treat); liver biopsy to determine extent of damage
HCV - Virion and Genome
enveloped, + ssRNA produces a single polyprotein; mutates rapidly due to high error rate of RNA-dependent RNA polymerase; E1 and E2 envelope glycoproteins (mediate receptor binding and entry)
HCV - Clinical Picture
15-150 day incubation period; most infections are insidious (slow); 10 years to clinical hepatitis, 21 years to liver cirrhosis, 29 years to develop hepatocellular carcinoma
HCV - Treatment
combination of pegylated interferon alpha and the antiviral drug ribavirin for 24-48 weeks depending upon the genotype; ribavarin; more effective during the first six months as opposed to after infection has become chronic
HCV - Prevention
no vaccine
HCV - PEG
polyethylene glycol used by pharmaceutical companies; stabilizing agent, slowed clearance from the blood, enhanced permeability and retention in tumors
HCV - New Drugs
direct acting antivirals; remove all traces of the virus from the blood in 12 weeks; sustained viriologic response; treatment varies from 8-24 weeks; now called the IFN free era
HCV - NS3/4A Viral Protein
viral protease (polyprotein processing); target for protease inhibitors (glecaprevir, grazoprevir, voxilaprevir)
HCV - NS5A Viral Protein
organizes viral RNA replication complexes and helps assemble new virions; target for inhibitors (velpatasvir, pibrentasvir, ledipasvir)
HCV - NS5B Viral Protein
RNA dependent RNA polymerase that synthesizes viral RNA; target for polymerase inhibitors (sofosbuvir)
Hepatits D Virus (HDV)
transmission is bloodborne, sexual, needle sharing, infected blood products; incubation period is 30-60 days
HDV - Clinical Symptoms
more severe than other hepatitis viruses; abdominal pain and swelling, loss of appetite, sore throat, joint and muscle pain, clay-colored or pale stools, dark urine, fatigue, fever, itching, jaundice, nausea, vomiting
HDV - Immune Response
anti-HD antibodies do not always persist after acute infection is cleared
HDV - Diagnosis
anti-delta/HD antibodies; serum RNA
HDV - Virion
defective RNA virus that requires hepatitis B surface proteins (HBsAg) for assembly and release, infection occurs only in people with current HBV infection; uses HBsAg to assemble its envelope and exit infected hepatocytes; replicates (-) ssRNA using host enzymes, independent of HBV polymerase; has a delta antigen
HDV - Large HBsAg
enables HDV attachment to the hepatocyte receptor NTCP and entry into cells
HDV - HBV Vaccination
also prevents infection by preventing the HBV infection needed to supply HBsAg
HDV - Treatment
no effective antivirals; progression to cirrhosis usually takes 5-10 years, but it can appear 2 years after infection onset; about 60-70% of patients develop cirrhosis and die from hepatic failure; liver transplant may be considered for fulminant acute or end stage chronic disease; mortality is 10x higher than HBV alone
HEV - Transmission
fecal oral route; primarily via contaminated water due to poor sanitation; incubation period of 15-60 days
HEV - Clinical Symptoms
jaundice, dark urine, pale stools, anorexia, enlarged/tender liver, abdominal pain and tenderness, nausea and vomiting, fever
HEV - Immune Response
noncytopathic (does not directly kill cells), but suspected to cause immune-mediated liver damage through cytotoxic T cells
HEV - Diagnosis
detection of specific anti-HEV antibodies in blood; often associated with outbreaks (ex, waterborne)
HEV - Virion
non enveloped; ORF2 capsid protein; + ssRNA
HEV - Treatment
none available; usually self limiting; hospitalization required for patients with fulminant disease
HEV - Prevention
maintain quality standards for public water supplies; proper disposal and treatment of waste; vaccine available in china, but not in the U.S.
Orthomyxoviruses
negative sense ssRNA; mRNA is in the positive sense *must be converted to positive sense mRNA before translation); segmented genome allows for gene re-assortment; alpha, neta, gamma, delta genera
Influenza
respiratory infection; incubation period is 1-4 days, lasts 1-2 weeks; complications include pneumonia, bronchitis, sinusitis, croup, COPD, exacerbation, reye’s syndrome, inflammation of the heart, muscles, or pericardium
High Fever and Muscle/Joint Pain
what sets the flu apart from common cold
Influenza Transmission
mostly through the air by respiratory park caused by coughs and sneezes (not long lasting in the air); from infected birds through their droppings; also by saliva, nasal secretions, feces, and blood
Influenza Virion
relatively labile (easy to degrade) because of the phospholipid bilayer; needs to stay hydrated to survive; easily destroyed by detergent; survive several hours in mucus
Structure of the Influenza Virion and Its Genome Segments
has HA/NA; 8 RNA genome segments, each encoding one or more viral proteins → enables genetic reassortment; vRnP complex of each gene that consists of RNA polymerases and NP-coated viral RNA
Influenza RNP Packaging - Segment Packaging Signals
located near the 3’ and 5’ ends of each viral RNA segment and extend into adjacent coding regions; help distinguish one segment from another
Influenza RNP Packaging - Segment Recognition
specific RNA interactions help bring different viral ribonucleoprotein complexes together into a coordinated set
Influenza RNP Packaging - Segment Assembly
forms a 7+1 pattern; electron microscopy shows seven vRNPs surrounding one central vRNP
Influenza RNP Packaging - Assembled Genome
incorporated into a budding virion; viral proteins, including M1 and the membrane associated machinery help coordinate genome incorporation during budding
Influenza Replication Cycle
adhesion → endocytosis → pH triggers conformational change → fusion and uncoating → replication and protein synthesis → assembly → budding → release
Influenza Antigenic Drift
error-prone RNA dependent RNA polymerase; point mutations in multiple antigenic sites of HA; eventually virus is no longer effectively neutralized by antibodies to parent virus; vaccine will no longer prevent disease; humans mat still have some protection lessening severity → seasonal flu requires new vaccine each year
Influenza Antigenic Shift
segmented genome allows for reassortment of HA and NA genes; occurs in cells infected with different human and animal viruses; resulting virus has novel antigenic properties; humans have no protection; disease can be severe → causes human epidemics/pandemics
Influenza Hemagglutinin (HA)
binds to sialic acid receptors; mediates membrane fusion into the endosome; binds to proteoglycans on the cell surface that terminate in sialic acid
Influenza Neuraminidase (NA)
glycoside hydrolase that cleaves sialic acid; releases particles after maturation; breaks down mucins in respiratory tract
a2,3-sialyated Glycans
avian like, deeper in the lungs; when bound by influenza, produces a slower spread but more fatal disease
a2,6-sialyated Glycans
human like, more shallow in the lungs; when bound by influenza, produces a faster spreading but milder disease